Ofloxacin for prevention of bacterial infections in granulocytopenic patients

[1]  W. Kern,et al.  High risk of streptococcal septicemia after high dose cytosine arabinoside treatment for acute myelogenous leukemia , 1987, Klinische Wochenschrift.

[2]  W. Gaus,et al.  Prevention of infection in acute leukemia: A prospective randomized study on the efficacy of two different drug regimens for antimicrobial prophylaxis , 1986, Infection.

[3]  D. Reeves,et al.  Effect of oral ciprofloxacin on the faecal flora of healthy volunteers , 1986, European Journal of Clinical Microbiology.

[4]  H. Heimpel,et al.  Antimicrobial prophylaxis in acute leukaemia: Prospective randomized study comparing two methods of selective decontamination , 1983, Klinische Wochenschrift.

[5]  J. Verhoef,et al.  Colistin and trimethoprim-sulfamethoxazole for the prevention of infection in patients with acute non-lymphocytic leukaemia. Decrease in the emergence of resistant bacteria , 1983, Infection.

[6]  D. Bruckner,et al.  Ofloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. , 1990, The American journal of medicine.

[7]  J. Bartlett,et al.  Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. , 2020, Annals of internal medicine.

[8]  D. Dennig,et al.  Chemoprophylaxis of bacterial infections in granulocytopenic patients with ciprofloxacin. , 1987, Onkologie.

[9]  J. Verhoef,et al.  Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. , 1987, Annals of internal medicine.

[10]  C. Nord,et al.  Effect of norfloxacin on human oropharyngeal and colonic microflora and multiple-dose pharmacokinetics. , 1987, Scandinavian journal of infectious diseases.

[11]  A. Andremont,et al.  Selective antimicrobial modulation of the intestinal tract by norfloxacin in human volunteers and in gnotobiotic mice associated with a human fecal flora , 1986, Antimicrobial Agents and Chemotherapy.

[12]  R. Champlin,et al.  Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. , 1986, The American journal of medicine.

[13]  M. Rozenberg-Arska,et al.  Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora. , 1985, The Journal of infectious diseases.

[14]  A. Korn,et al.  Dose linearity and other pharmacokinetics of ofloxacin: a new, broad-spectrum antimicrobial agent. , 1985, Pharmatherapeutica.

[15]  J. Hamilton-miller,et al.  Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers , 1984, Antimicrobial Agents and Chemotherapy.

[16]  S. Henry.  Chemoprophylaxis of bacterial infections in granulocytopenic patients , 1984 .

[17]  A. Brown.  Neutropenia, fever, and infection. , 1984, The American journal of medicine.

[18]  B. Bostrom,et al.  STREPTOCOCCAL SEPSIS IN BONE MARROW TRANSPLANT PATIENTS , 1984, The Lancet.

[19]  T. Louie,et al.  Randomized controlled trial comparing trimethoprim/sulfamethoxazole and trimethoprim for infection prophylaxis in hospitalized granulocytopenic patients. , 1984, The American journal of medicine.

[20]  織田 実,et al.  Lenampicillin hydrochloride (KBT-1585) の抗原性について , 1984 .

[21]  Trimethoprim-sulfamethoxazole in the prevention of infection in neutropenic patients. EORTC International Antimicrobial Therapy Project Group. , 1984, The Journal of infectious diseases.

[22]  R. Wise,et al.  The pharmacokinetics and tissue penetration of norfloxacin. , 1984, The Journal of antimicrobial chemotherapy.

[23]  R. Wise,et al.  The pharmacokinetics and tissue penetration of ofloxacin. , 1984, The Journal of antimicrobial chemotherapy.

[24]  D. Catovsky,et al.  SEPTICAEMIA CAUSED BY VIRIDANS STREPTOCOCCI IN NEUTROPENIC PATIENTS WITH LEUKAEMIA , 1983, The Lancet.

[25]  C. Kauffman.  TRIMETHOPRIM/SULFAMETHOXAZOLE PROPHYLAXIS IN NEUTROPENIC PATIENTS , 1983 .

[26]  D. Kaiser,et al.  Double-blind randomized study of prophylactic trimethoprim/sulfamethoxazole in granulocytopenic patients with hematologic malignancies. , 1983, The American journal of medicine.

[27]  C. Kauffman,et al.  Trimethoprim/sulfamethoxazole prophylaxis in neutropenic patients. Reduction of infections and effect on bacterial and fungal flora. , 1983, The American journal of medicine.

[28]  J. Crowley,et al.  Selective antimicrobial modulation as prophylaxis against infection during granulocytopenia: trimethoprim-sulfamethoxazole vs. nalidixic acid. , 1983, The Journal of infectious diseases.

[29]  L. Young.  Antimicrobial prophylaxis against infection in neutropenic patients. , 1983, The Journal of infectious diseases.

[30]  J. M. Wilson,et al.  Failure of oral trimethoprim-sulfamethoxazole prophylaxis in acute leukemia: isolation of resistant plasmids from strains of Enterobacteriaceae causing bacteremia. , 1982, The New England journal of medicine.

[31]  I. Judson,et al.  CO-TRIMOXAZOLE VERSUS NON-ABSORBABLE ANTIBIOTICS IN ACUTE LEUKAEMIA , 1982, The Lancet.

[32]  J. Sixma,et al.  Prevention of infection by trimethoprim-sulfamethoxazole plus amphotericin B in patients with acute nonlymphocytic leukaemia. , 1981, Annals of internal medicine.